• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma.多发性骨髓瘤患者对两剂新冠病毒RNA疫苗的严重急性呼吸综合征冠状病毒2刺突抗体反应高度可变。
Cancer Cell. 2021 Aug 9;39(8):1028-1030. doi: 10.1016/j.ccell.2021.06.014. Epub 2021 Jun 29.
2
Loss of anti-spike antibodies following mRNA vaccination for COVID-19 among patients with multiple myeloma.mRNA 疫苗接种 COVID-19 后多发性骨髓瘤患者抗刺突抗体丢失。
Cancer Rep (Hoboken). 2023 May;6(5):e1803. doi: 10.1002/cnr2.1803. Epub 2023 Mar 9.
3
Response to COVID-19 mRNA vaccination in multiple myeloma is conserved but impaired compared to controls.多发性骨髓瘤患者对 COVID-19 mRNA 疫苗的反应与对照组相比是保守的，但受到了损害。
J Hematol Oncol. 2021 Oct 13;14(1):166. doi: 10.1186/s13045-021-01183-2.
4
Immune response to SARS-CoV-2 mRNA vaccination and booster dose in patients with multiple myeloma and monoclonal gammopathies: impact of Omicron variant on the humoral response.免疫应答：SARS-CoV-2 mRNA 疫苗接种和加强剂在多发性骨髓瘤和单克隆丙种球蛋白病患者中的作用：Omicron 变异对体液免疫应答的影响。
Oncoimmunology. 2022 Sep 6;11(1):2120275. doi: 10.1080/2162402X.2022.2120275. eCollection 2022.
5
Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.真实世界中衰弱老年人接受延长间隔和异源 COVID-19 mRNA 疫苗接种后的血清学反应（UNCoVER）：一项前瞻性观察队列研究的中期报告。
Lancet Healthy Longev. 2022 Mar;3(3):e166-e175. doi: 10.1016/S2666-7568(22)00012-5. Epub 2022 Feb 23.
6
Cellular mechanisms associated with sub-optimal immune responses to SARS-CoV-2 bivalent booster vaccination in patients with Multiple Myeloma.与多发性骨髓瘤患者对 SARS-CoV-2 二价加强疫苗免疫反应欠佳相关的细胞机制。
EBioMedicine. 2023 Dec;98:104886. doi: 10.1016/j.ebiom.2023.104886. Epub 2023 Nov 22.
7
Post-vaccination SARS-CoV-2 IgG spike antibody responses among clinical and non-clinical healthcare workers at a tertiary facility in Kenya.肯尼亚一家三级医疗机构中临床和非临床医护人员接种疫苗后的 SARS-CoV-2 IgG 刺突抗体反应。
PLoS One. 2024 Apr 4;19(4):e0299302. doi: 10.1371/journal.pone.0299302. eCollection 2024.
8
Antibody and T cell responses to COVID-19 vaccination in patients receiving anticancer therapies.癌症治疗患者接种 COVID-19 疫苗后的抗体和 T 细胞反应。
J Immunother Cancer. 2022 Jun;10(6). doi: 10.1136/jitc-2022-004766.
9
Vaccine-Induced Antibody Responses against SARS-CoV-2 Variants-Of-Concern Six Months after the BNT162b2 COVID-19 mRNA Vaccination.辉瑞-BioNTech 新冠疫苗接种 6 个月后针对 SARS-CoV-2 关注变异株的抗体反应
Microbiol Spectr. 2022 Apr 27;10(2):e0225221. doi: 10.1128/spectrum.02252-21. Epub 2022 Mar 9.
10
Time of Day of Vaccination Affects SARS-CoV-2 Antibody Responses in an Observational Study of Health Care Workers.接种时间影响医护人员观察性研究中 SARS-CoV-2 抗体反应。
J Biol Rhythms. 2022 Feb;37(1):124-129. doi: 10.1177/07487304211059315. Epub 2021 Dec 4.

引用本文的文献

1
Circulating SARS-CoV-2 spike IgG antibody responses in cancer patients following multiple COVID-19 vaccination boosters.癌症患者多次接种新冠病毒疫苗加强针后的循环严重急性呼吸综合征冠状病毒2刺突蛋白IgG抗体反应
Front Immunol. 2025 Aug 12;16:1629473. doi: 10.3389/fimmu.2025.1629473. eCollection 2025.
2
Humoral vaccine responses following Chimeric Antigen Receptor T-cell therapy for hematological malignancies.嵌合抗原受体T细胞疗法治疗血液系统恶性肿瘤后的体液疫苗反应。
Blood Cancer J. 2025 Jul 2;15(1):114. doi: 10.1038/s41408-025-01321-w.
3
T-Cell Redirecting Therapies in Multiple Myeloma: Pathogenesis and Management of Toxicities Beyond CRS and ICANS.多发性骨髓瘤中的T细胞重定向疗法：细胞因子释放综合征和免疫效应细胞相关神经毒性综合征之外的发病机制及毒性管理
Cancers (Basel). 2025 Apr 30;17(9):1514. doi: 10.3390/cancers17091514.
4
Follow-up of humoral and cellular immune responses after the third SARS-CoV-2 vaccine dose in multiple myeloma patients.多发性骨髓瘤患者接种第三剂严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫苗后的体液和细胞免疫反应随访
Front Immunol. 2025 Feb 18;16:1532947. doi: 10.3389/fimmu.2025.1532947. eCollection 2025.
5
SARS-CoV-2 immune responses in patients with multiple myeloma and lenalidomide maintenance therapy.多发性骨髓瘤患者的SARS-CoV-2免疫反应及来那度胺维持治疗
Front Immunol. 2024 Dec 18;15:1510942. doi: 10.3389/fimmu.2024.1510942. eCollection 2024.
6
Mucosal SARS-CoV-2 S1 adenovirus-based vaccine elicits robust systemic and mucosal immunity and protects against disease in animals.基于腺病毒的黏膜严重急性呼吸综合征冠状病毒2刺突蛋白1疫苗可引发强大的全身和黏膜免疫，并在动物中预防疾病。
mBio. 2025 Jan 8;16(1):e0217024. doi: 10.1128/mbio.02170-24. Epub 2024 Dec 4.
7
Bispecific antibodies in the treatment of multiple myeloma.双特异性抗体在多发性骨髓瘤治疗中的应用。
Blood Cancer J. 2024 Sep 12;14(1):158. doi: 10.1038/s41408-024-01139-y.
8
Patients with multiple myeloma infected with COVID-19 during autologous stem cell transplantation.在自体干细胞移植期间感染新冠病毒的多发性骨髓瘤患者。
Infect Agent Cancer. 2024 Aug 12;19(1):38. doi: 10.1186/s13027-024-00603-5.
9
Managing and treating COVID-19 in patients with hematological malignancies: a narrative review and expert insights.管理和治疗血液系统恶性肿瘤患者的 COVID-19：叙述性综述和专家观点。
Clin Exp Med. 2024 Jun 4;24(1):119. doi: 10.1007/s10238-024-01381-5.
10
Breakthrough Infections in SARS-CoV-2-Vaccinated Multiple Myeloma Patients Improve Cross-Protection against Omicron Variants.接种SARS-CoV-2疫苗的多发性骨髓瘤患者中的突破性感染改善了对奥密克戎变种的交叉保护。
Vaccines (Basel). 2024 May 9;12(5):518. doi: 10.3390/vaccines12050518.

本文引用的文献

1
Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer.mRNA 疫苗在癌症患者中的免疫原性。
Cancer Cell. 2021 Aug 9;39(8):1091-1098.e2. doi: 10.1016/j.ccell.2021.06.009. Epub 2021 Jun 18.
2
Seroconversion rates following COVID-19 vaccination among patients with cancer.癌症患者接种 COVID-19 疫苗后的血清转化率。
Cancer Cell. 2021 Aug 9;39(8):1081-1090.e2. doi: 10.1016/j.ccell.2021.06.002. Epub 2021 Jun 5.
3
Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series.实体器官移植受者接种第三剂新冠病毒疫苗的安全性和免疫原性：病例系列
Ann Intern Med. 2021 Sep;174(9):1330-1332. doi: 10.7326/L21-0282. Epub 2021 Jun 15.
4
Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution.第五周抗 SARS-CoV-2 BNT162b2 疫苗在接受积极治疗的多发性骨髓瘤和骨髓增生性恶性肿瘤患者中的免疫原性和安全性：来自单一机构的初步数据。
J Hematol Oncol. 2021 May 17;14(1):81. doi: 10.1186/s13045-021-01090-6.
5
Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study.癌症患者接种一剂与两剂新冠疫苗BNT162b2的安全性和免疫原性：一项前瞻性观察研究的中期分析
Lancet Oncol. 2021 Jun;22(6):765-778. doi: 10.1016/S1470-2045(21)00213-8. Epub 2021 Apr 27.
6
Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma.多发性骨髓瘤患者对严重急性呼吸综合征冠状病毒2首次疫苗接种的反应。
Lancet Haematol. 2021 Jun;8(6):e389-e392. doi: 10.1016/S2352-3026(21)00110-1. Epub 2021 Apr 19.
7
Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose.骨髓瘤老年患者在接种第一剂BNT162b2疫苗后对新冠病毒的中和抗体反应较低。
Blood. 2021 Jul 1;137(26):3674-3676. doi: 10.1182/blood.2021011904.
8
Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2.先前感染过 SARS-CoV-2 的个体对 BNT162b2 mRNA 疫苗的抗体反应。
Nat Med. 2021 Jun;27(6):981-984. doi: 10.1038/s41591-021-01325-6. Epub 2021 Apr 1.
9
Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine.单剂 SARS-CoV-2 mRNA 疫苗接种后血清阳性者的抗体反应。
N Engl J Med. 2021 Apr 8;384(14):1372-1374. doi: 10.1056/NEJMc2101667. Epub 2021 Mar 10.
10
A serological assay to detect SARS-CoV-2 seroconversion in humans.用于检测人类 SARS-CoV-2 血清转化的血清学检测方法。
Nat Med. 2020 Jul;26(7):1033-1036. doi: 10.1038/s41591-020-0913-5. Epub 2020 May 12.

Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma.

作者信息

Van Oekelen Oliver, Gleason Charles R, Agte Sarita, Srivastava Komal, Beach Katherine F, Aleman Adolfo, Kappes Katerina, Mouhieddine Tarek H, Wang Bo, Chari Ajai, Cordon-Cardo Carlos, Krammer Florian, Jagannath Sundar, Simon Viviana, Wajnberg Ania, Parekh Samir

机构信息

Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Medicine, Hematology, and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

出版信息

Cancer Cell. 2021 Aug 9;39(8):1028-1030. doi: 10.1016/j.ccell.2021.06.014. Epub 2021 Jun 29.

DOI:10.1016/j.ccell.2021.06.014
PMID:34242572
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8238657/
Abstract
摘要